Achondroplasia FGFR3, Short stature
Conditions
Interventions
Administered MECLIZIN oraly once a daily for 26 weeks.
Sponsors
Matsushita Masaki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have been confirmed to Definite or Probable among the achondroplasia diagnostic criteria created by the Intractable Diseases Research Group of the Ministry of Health, Labor and Welfare more than one year before obtaining consent. 2) Patients whose age at the time of obtaining consent is 5 to 11 years old. 3)Patients with documented height data between 12 and 3 months prior to enrollment
Exclusion criteria
Exclusion criteria: 1) Patients who started treatment with a growth hormone preparation within 1.5 years (78 weeks) before obtaining informed consent 2) Patients who have been treated with drugs (CNP analogues, statins, etc.) for which basic or clinical data have been reported to suppress FGFR3 signals within 1 year before obtaining informed consent 3) Patients who have taken medicines such as motion sickness medicines containing meclizine hydrochloride continuously for more than 2 weeks within 1 year before obtaining informed consent, expecting bone lengthening effects. 4) Patients who have undergone bone lengthening surgery within 1 year or patients who are planning to perform bone lengthening surgery during the study drug administration period 5)Pregnant, lactating, or potentially pregnant female patients, or both male and female patients who cannot agree to use contraception during the study period under the guidance of the princepal investigator or subinvestigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety: Safety data for 7 months from the first treatment Efficacy: Growth rate | — |
Contacts
Public ContactYuichi Kato
Nagoya University Hospital
Outcome results
None listed